617 related articles for article (PubMed ID: 23161513)
1. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
Demory Beckler M; Higginbotham JN; Franklin JL; Ham AJ; Halvey PJ; Imasuen IE; Whitwell C; Li M; Liebler DC; Coffey RJ
Mol Cell Proteomics; 2013 Feb; 12(2):343-55. PubMed ID: 23161513
[TBL] [Abstract][Full Text] [Related]
2. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.
Dou Y; Cha DJ; Franklin JL; Higginbotham JN; Jeppesen DK; Weaver AM; Prasad N; Levy S; Coffey RJ; Patton JG; Zhang B
Sci Rep; 2016 Nov; 6():37982. PubMed ID: 27892494
[TBL] [Abstract][Full Text] [Related]
3. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.
Shang A; Gu C; Zhou C; Yang Y; Chen C; Zeng B; Wu J; Lu W; Wang W; Sun Z; Li D
Cell Commun Signal; 2020 Mar; 18(1):52. PubMed ID: 32228650
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
[TBL] [Abstract][Full Text] [Related]
5. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
6. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.
Halvey PJ; Ferrone CR; Liebler DC
J Proteome Res; 2012 Jul; 11(7):3908-13. PubMed ID: 22671702
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
10. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
Kikuchi H; Pino MS; Zeng M; Shirasawa S; Chung DC
Cancer Res; 2009 Nov; 69(21):8499-506. PubMed ID: 19843849
[TBL] [Abstract][Full Text] [Related]
12. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
13. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
[TBL] [Abstract][Full Text] [Related]
14. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
Guha U; Chaerkady R; Marimuthu A; Patterson AS; Kashyap MK; Harsha HC; Sato M; Bader JS; Lash AE; Minna JD; Pandey A; Varmus HE
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14112-7. PubMed ID: 18776048
[TBL] [Abstract][Full Text] [Related]
16. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
17. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
Brandi G; Tavolari S; De Rosa F; Di Girolamo S; Agostini V; Barbera MA; Frega G; Biasco G
PLoS One; 2012; 7(7):e41347. PubMed ID: 22911782
[TBL] [Abstract][Full Text] [Related]
19. Amphiregulin exosomes increase cancer cell invasion.
Higginbotham JN; Demory Beckler M; Gephart JD; Franklin JL; Bogatcheva G; Kremers GJ; Piston DW; Ayers GD; McConnell RE; Tyska MJ; Coffey RJ
Curr Biol; 2011 May; 21(9):779-86. PubMed ID: 21514161
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]